{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:16:32Z","timestamp":1788189392304,"version":"build-2803163510"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"1206","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment of Graves\u2019 disease (GD) is complex and controversial. Conventional therapy of GD includes antithyroid drugs (ATDs), surgery, and radio-iodine therapy (RIT) and each has limitations. ATDs are associated with high rates of relapse and side effects. Definitive therapies result in permanent hypothyroidism and increased risk of Graves\u2019 ophthalmopathy. With advancements in the understanding of precise autoimmune mechanisms causing GD, novel therapies targeting immune pathways are in the pipeline of development. Newer drugs switch off a part of the immune system that is causing the disease, leaving the rest of the immune system still functioning. Though newer drugs seem to be efficacious, they may elicit higher incidence of infection and other side effects. Other concerns with newer drugs are that they may not be able to cure the disease, do not achieve adequate effectiveness in all patients, and may not achieve remission in all patients. Therefore, additional newer drugs will be needed in future.<\/jats:p>","DOI":"10.1093\/postmj\/qgaf197","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:51:15Z","timestamp":1763574675000},"page":"302-310","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in management of Graves\u2019 disease: an update"],"prefix":"10.1093","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-5691","authenticated-orcid":false,"given":"Shailendra Kumar","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Endocrine, Endocrine Clinic , Gilat Bazar, Varanasi, Uttar Pradesh, 221002 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Endocrine, Endocrine Clinic , Gilat Bazar, Varanasi, Uttar Pradesh, 221002 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Kumar","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Lucknow Endocrine Diabetes and Thyroid Clinic , 2\/1 Vivek Khand, Gomtinagar, Lucknow, Uttar Pradesh, 226010 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanshika","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King George\u2019s Medical University , Lucknow, Uttar Pradesh, 226003 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alankar","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Endocrine, Diabetes and Endocrine Care Superspeciality Clinic , Varanasi, Uttar Pradesh, 221005 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep Kumar","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Opal Hospital , Varanasi, Uttar Pradesh, 221006 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2026031710055633300_ref1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves\u2019 disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"},{"key":"2026031710055633300_ref2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"2026031710055633300_ref3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026031710055633300_ref4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026031710055633300_ref5","doi-asserted-by":"publisher","first-page":"e3768","DOI":"10.1210\/clinem\/dgaf144","article-title":"Clinical phenotype of Graves disease in autoimmune polyglandular syndrome or as isolated disease: the GRAPHE study","volume":"110","author":"Gatta","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref6","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of Graves thyroidal and extrathyroidal disease: an update","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for Graves\u2019 hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev"},{"key":"2026031710055633300_ref8","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1210\/jc.2003-030185","article-title":"Antithyroid drugs in the management of patients with Graves\u2019 disease: an evidence-based approach to therapeutic controversies","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"2026031710055633300_ref10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"2026031710055633300_ref11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1089\/thy.2010.1640","article-title":"The tale of radioiodine and Graves\u2019 orbitopathy","volume":"20","author":"Ponto","year":"2010","journal-title":"Thyroid"},{"key":"2026031710055633300_ref12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MED.0000000000000561","article-title":"Cancer incidence and mortality following treatment of hyperthyroidism with radioactive iodine","volume":"27","author":"Evron","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026031710055633300_ref13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr Rev"},{"key":"2026031710055633300_ref14","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/hmg\/ddr247","article-title":"Association of an SNP with intrathymic transcription of TSHR and Graves\u2019 disease: a role for defective thymic tolerance","volume":"20","author":"Colobran","year":"2011","journal-title":"Hum Mol Genet"},{"key":"2026031710055633300_ref15","doi-asserted-by":"crossref","first-page":"e210024","DOI":"10.1530\/ETJ-21-0024","article-title":"Cellular and molecular basis of thyroid autoimmunity","volume":"11","author":"Bogus\u0142awska","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026031710055633300_ref16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2026031710055633300_ref17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0167-5699(93)90317-E","article-title":"Multiple levels of peripheral tolerance","volume":"14","author":"Arnold","year":"1993","journal-title":"Immunol Today"},{"key":"2026031710055633300_ref18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","article-title":"Graves disease: latest understanding of pathogenesis and treatment options","volume":"20","author":"Lanzolla","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026031710055633300_ref19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12020-020-02337-x","article-title":"Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves\u2019 disease: susceptibility and clinical features","volume":"71","author":"Bufalo","year":"2021","journal-title":"Endocrine"},{"key":"2026031710055633300_ref20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.aace.2024.12.002","article-title":"Mild thyrotoxicosis due to seronegative Graves\u2019 disease or disseminated thyroid autonomy","volume":"11","author":"Charbonne","year":"2024","journal-title":"AACE Clin Case Rep"},{"key":"2026031710055633300_ref21","first-page":"159","article-title":"Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes","volume":"3","author":"Pujol-Borrell","year":"1986","journal-title":"Mol Biol Med"},{"key":"2026031710055633300_ref22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/medicina61030500","article-title":"Graves\u2019 disease: is it time for targeted therapy? A narrative review","volume":"61","author":"Viola","year":"2025","journal-title":"Medicina"},{"key":"2026031710055633300_ref23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","article-title":"Immunogenetics of autoimmune thyroid diseases: a comprehensive review","volume":"64","author":"Lee","year":"2015","journal-title":"J Autoimmun"},{"key":"2026031710055633300_ref24","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2026031710055633300_ref25","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"2026031710055633300_ref26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctrv.2016.11.015","article-title":"Rituximab: 13 open questions after 20 years of clinical use","volume":"53","author":"Pavanello","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026031710055633300_ref27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves\u2019 disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2026031710055633300_ref29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant rituximab\u2014exploratory trial in young people with Graves disease","volume":"107","author":"Cheetham","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","year":"2013","journal-title":"Clin Endocrinol"},{"key":"2026031710055633300_ref31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2026031710055633300_ref32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"2026031710055633300_ref33","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"key":"2026031710055633300_ref34","doi-asserted-by":"crossref","first-page":"dgz013","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, Iscalimab, for control of Graves hyperthyroidism\u2014a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.smim.2009.05.008","article-title":"Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis","volume":"21","author":"Munroe","year":"2009","journal-title":"Semin Immunol"},{"key":"2026031710055633300_ref36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"2026031710055633300_ref37","doi-asserted-by":"publisher","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front Neurol"},{"key":"2026031710055633300_ref38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"2026031710055633300_ref39","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, Batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref40","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"2026031710055633300_ref41","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/thy.2015.0029","article-title":"BCell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases","volume":"25","author":"Campi","year":"2015","journal-title":"Thyroid"},{"key":"2026031710055633300_ref42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2016.09.004","article-title":"Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease","volume":"462","author":"Lin","year":"2016","journal-title":"Clin Chim Acta"},{"key":"2026031710055633300_ref43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cen.13872","article-title":"Analysis of BAFF gene polymorphisms in UK Graves\u2019 disease patients","volume":"90","author":"Lane","year":"2019","journal-title":"Clin Endocrinol"},{"key":"2026031710055633300_ref44","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1210\/en.2006-0507","article-title":"Treatment of autoimmune hyperthyroidism in a murine model of Graves\u2019 disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology","volume":"147","author":"Gilbert","year":"2006","journal-title":"Endocrinology"},{"key":"2026031710055633300_ref45","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70\u2122 targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy\u2014results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026031710055633300_ref46","doi-asserted-by":"publisher","first-page":"OP3","DOI":"10.1530\/endoabs.104.OP3","article-title":"Immunomodulation of severe Graves\u2019 disease: Graves\u2019-plasma cell depletion (PCD) trial","volume":"104","author":"Grixiti","year":"2024","journal-title":"Endocr Abstr"},{"key":"2026031710055633300_ref47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/sjopt.sjopt_179_23","article-title":"Teprotumumab in thyroid eye disease","volume":"38","author":"Goldberg","year":"2024","journal-title":"Saudi J Ophthalmol"},{"key":"2026031710055633300_ref48","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"2026031710055633300_ref49","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology"},{"key":"2026031710055633300_ref50","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"key":"2026031710055633300_ref51","doi-asserted-by":"crossref","first-page":"5727516","DOI":"10.1155\/2019\/5727516","article-title":"Immunotherapy deriving from CAR-T cell treatment in autoimmune diseases","volume":"2019","author":"Chen","year":"2019","journal-title":"J Immunol Res"},{"key":"2026031710055633300_ref52","doi-asserted-by":"publisher","first-page":"110873","DOI":"10.1016\/j.intimp.2023.110873","article-title":"TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease","volume":"124","author":"Duan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2026031710055633300_ref53","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.intimp.2011.08.003","article-title":"Inhibitory effect of cepharanthine on dendritic cell activation and function","volume":"11","author":"Uto","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"2026031710055633300_ref54","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1074\/jbc.M115.694687","article-title":"Identifying a Small-Molecule blocking antigen presentation in autoimmune thyroiditis","volume":"291","author":"Li","year":"2016","journal-title":"J Biol Chem"},{"key":"2026031710055633300_ref55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/5584_2018_246","article-title":"Immunomodulatory role of vitamin D: a review","volume":"1108","author":"Skrobot","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2026031710055633300_ref56","doi-asserted-by":"publisher","first-page":"574967","DOI":"10.3389\/fimmu.2021.574967","article-title":"Immunomodulatory function of vitamin D and its role in autoimmune thyroid disease","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2026031710055633300_ref57","doi-asserted-by":"publisher","first-page":"956181","DOI":"10.3389\/fimmu.2022.956181","article-title":"Immunomodulatory roles of selenium nanoparticles: novel arts for potential immunotherapy strategy development","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2026031710055633300_ref58","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.3390\/nu16193324","article-title":"The immunomodulatory effects of selenium: a journey from the environment to the human immune system","volume":"16","author":"Sadler","year":"2024","journal-title":"Nutrients"},{"key":"2026031710055633300_ref59","doi-asserted-by":"publisher","first-page":"886451","DOI":"10.3389\/fendo.2022.886451","article-title":"Add-on effect of selenium and vitamin D combined supplementation in early control of Graves\u2019 disease hyperthyroidism during methimazole treatment","volume":"13","author":"Gallo","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026031710055633300_ref60","doi-asserted-by":"publisher","first-page":"1145811","DOI":"10.3389\/fendo.2023.1145811","article-title":"Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves\u2019 disease patients during methimazole treatment","volume":"14","author":"Gallo","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026031710055633300_ref61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s44337-024-00029-3","article-title":"The potential of immunomodulators in shaping the future of healthcare","volume":"1","author":"Sharma","year":"2024","journal-title":"Discov Med"},{"key":"2026031710055633300_ref62","first-page":"8","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Acta Endocrinol"},{"key":"2026031710055633300_ref63","doi-asserted-by":"publisher","first-page":"1168936","DOI":"10.3389\/fendo.2023.1168936","article-title":"Azathioprine as an adjuvant therapy in severe Graves\u2019 disease: a randomized controlled open-label clinical trial","volume":"14","author":"Allam","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026031710055633300_ref64","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026031710055633300_ref65","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/clinem\/dgae472","article-title":"Effects of low-dose methotrexate with methimazole in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"110","author":"Xie","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/ajhp\/54.3.285","article-title":"Mycophenolate mofetil: a unique immunosuppressive agent","volume":"54","author":"Hood","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"2026031710055633300_ref67","doi-asserted-by":"publisher","first-page":"1140196","DOI":"10.3389\/fendo.2023.1140196","article-title":"Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026031710055633300_ref68","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1210\/jc.2010-1935","article-title":"A new small-molecule antagonist inhibits Graves\u2019 disease antibody activation of the TSH receptor","volume":"96","author":"Neumann","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031710055633300_ref69","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"key":"2026031710055633300_ref70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves\u2019 orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1206\/302\/65396797\/qgaf197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1206\/302\/65396797\/qgaf197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:06:04Z","timestamp":1773756364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/102\/1206\/302\/8328257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":70,"journal-issue":{"issue":"1206","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgaf197","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,19]]}}}